Vermillion, Inc. (NASDAQ:VRML) saw a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 1,096,250 shares, a drop of 31.3% from the January 31st total of 1,596,565 shares. Based on an average daily volume of 106,988 shares, the days-to-cover ratio is presently 10.2 days. Currently, 3.1% of the shares of the company are short sold.
Several hedge funds have recently modified their holdings of VRML. Essex Investment Management Co. LLC grew its holdings in shares of Vermillion by 145.8% during the third quarter. Essex Investment Management Co. LLC now owns 216,607 shares of the company’s stock worth $390,000 after purchasing an additional 128,494 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Vermillion by 0.7% during the second quarter. Vanguard Group Inc. now owns 580,484 shares of the company’s stock worth $1,068,000 after purchasing an additional 4,200 shares during the last quarter. Finally, Birchview Capital LP grew its holdings in shares of Vermillion by 7.9% during the third quarter. Birchview Capital LP now owns 2,462,933 shares of the company’s stock worth $4,433,000 after purchasing an additional 180,000 shares during the last quarter. 34.62% of the stock is currently owned by institutional investors.
Shares of Vermillion (NASDAQ:VRML) traded up $0.01 during mid-day trading on Tuesday, hitting $1.39. The company’s stock had a trading volume of 18,274 shares, compared to its average volume of 68,690. The stock has a market capitalization of $83.46, a price-to-earnings ratio of -6.95 and a beta of 2.07. Vermillion has a 12 month low of $1.03 and a 12 month high of $2.43. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.38 and a current ratio of 2.42.
COPYRIGHT VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.dispatchtribunal.com/2018/03/21/short-interest-in-vermillion-inc-vrml-declines-by-31-3.html.
Vermillion Company Profile
Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.
Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.